摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4,4-Trifluoro-3-[[2-[3-(trifluoromethyl)phenyl]morpholin-4-yl]methyl]butanoic acid

中文名称
——
中文别名
——
英文名称
4,4,4-Trifluoro-3-[[2-[3-(trifluoromethyl)phenyl]morpholin-4-yl]methyl]butanoic acid
英文别名
4,4,4-trifluoro-3-[[2-[3-(trifluoromethyl)phenyl]morpholin-4-yl]methyl]butanoic acid
4,4,4-Trifluoro-3-[[2-[3-(trifluoromethyl)phenyl]morpholin-4-yl]methyl]butanoic acid化学式
CAS
——
化学式
C16H17F6NO3
mdl
——
分子量
385.3
InChiKey
LKMNJKSLJFYHIL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    10

文献信息

  • [EN] SUBSTITUTED PHENYLCARBAMATE COMPOUNDS<br/>[FR] COMPOSÉS SUBSTITUÉS DU PHÉNYLCARBAMATE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2014056958A1
    公开(公告)日:2014-04-17
    The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
    本发明涉及具有以下式(I)的化合物及其药用可接受的盐,其中Y,R1,R2和R3在详细说明和权利要求中有定义。此外,本发明涉及制备和使用具有式(I)的化合物的方法,以及含有这种化合物的药物组合物。式(I)的化合物是TRPA1通道的拮抗剂,可能在治疗与该通道相关的炎症性疾病和紊乱方面有用。
  • [EN] [3-HETEROARYL-2-TRIFLUOROMETHYL-PROPYL]-PIPERIDIN-1-YLE OR -MORPHOLIN-4-YLE COMPOUNDS AS TRPA1 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] COMPOSÉS [3-HÉTÉROARYL-2-TRIFLUOROMÉTHYL-PROPYL]-PIPÉRIDIN-1-YLE OU -MORPHOLIN-4-YLE EN TANT QU'ANTAGONISTES DE TRPA1 POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
    申请人:HOFFMANN LA ROCHE
    公开号:WO2014072325A1
    公开(公告)日:2014-05-15
    The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
    本发明涉及公式(I)的化合物及其药用可接受的盐。此外,本发明涉及制造和使用公式(I)化合物的方法,以及含有这种化合物的药物组合物。公式(I)化合物是TRPA1通道的拮抗剂,可能对治疗与该通道相关的炎症性疾病和紊乱有用。
  • SUBSTITUTED PHENYLCARBAMATE COMPOUNDS
    申请人:Hoffmann-La Roche Inc.
    公开号:US20150218144A1
    公开(公告)日:2015-08-06
    The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
    本发明涉及式(I)的化合物及其药学上可接受的盐,其中Y、R1、R2和R3在详细描述和权利要求中有定义。此外,本发明还涉及制造和使用式(I)化合物的方法以及含有这些化合物的药物组合物。式(I)的化合物是TRPA1通道拮抗剂,可能在治疗与该通道相关的炎症性疾病和紊乱方面有用。
  • [3-HETEROARYL-2-TRIFLUOROMETHYL-PROPYL]-PIPERIDIN-1-YLE OR -MORPHOLIN-4-YLE COMPOUNDS AS TRPA1 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISEASES
    申请人:F.Hoffmann-La Roche AG
    公开号:EP2917208A1
    公开(公告)日:2015-09-16
  • US9353096B2
    申请人:——
    公开号:US9353096B2
    公开(公告)日:2016-05-31
查看更多